KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Free Cash Flow (2017 - 2025)

Historic Free Cash Flow for Guardant Health (GH) over the last 9 years, with Q3 2025 value amounting to -$45.8 million.

  • Guardant Health's Free Cash Flow rose 1718.3% to -$45.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$262.2 million, marking a year-over-year increase of 442.01%. This contributed to the annual value of -$274.9 million for FY2024, which is 2041.27% up from last year.
  • Latest data reveals that Guardant Health reported Free Cash Flow of -$45.8 million as of Q3 2025, which was up 1718.3% from -$65.9 million recorded in Q2 2025.
  • Guardant Health's 5-year Free Cash Flow high stood at -$25.9 million for Q1 2021, and its period low was -$135.0 million during Q2 2022.
  • Moreover, its 5-year median value for Free Cash Flow was -$81.3 million (2021), whereas its average is -$77.4 million.
  • As far as peak fluctuations go, Guardant Health's Free Cash Flow plummeted by 32198.06% in 2021, and later soared by 5486.37% in 2024.
  • Quarter analysis of 5 years shows Guardant Health's Free Cash Flow stood at -$101.6 million in 2021, then rose by 0.85% to -$100.8 million in 2022, then grew by 17.81% to -$82.8 million in 2023, then dropped by 0.7% to -$83.4 million in 2024, then soared by 45.12% to -$45.8 million in 2025.
  • Its Free Cash Flow stands at -$45.8 million for Q3 2025, versus -$65.9 million for Q2 2025 and -$67.1 million for Q1 2025.